Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $126,673.94 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,627 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $126,673.94. Following the transaction, the chief operating officer now directly owns 26,961 shares of the company’s stock, valued at approximately $1,300,059.42. This represents a 8.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Peter Radovich also recently made the following trade(s):

• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total transaction of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM traded up $1.62 on Tuesday, reaching $50.21. The company’s stock had a trading volume of 410,214 shares, compared to its average volume of 511,828. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The firm has a market cap of $2.41 billion, a PE ratio of -24.86 and a beta of 0.96. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $50.34. The business has a 50-day moving average price of $44.39 and a 200 day moving average price of $42.02.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company’s quarterly revenue was up 89.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.57) earnings per share. Sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current year.

Institutional Trading of Mirum Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. grew its stake in Mirum Pharmaceuticals by 1.2% during the third quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock worth $256,245,000 after buying an additional 75,000 shares during the last quarter. State Street Corp lifted its position in shares of Mirum Pharmaceuticals by 19.9% during the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after purchasing an additional 297,511 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Mirum Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock worth $36,519,000 after purchasing an additional 29,017 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in shares of Mirum Pharmaceuticals during the third quarter worth approximately $28,913,000. Finally, Loomis Sayles & Co. L P acquired a new position in shares of Mirum Pharmaceuticals during the third quarter worth approximately $19,473,000.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on MIRM shares. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Leerink Partners upped their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.